Currently, novel treatments for HCC have been explored and assessed in in vitro and in vivo experiments and clinical trials targeting GPC-3, such as CAR T cell therapy (26), immunotoxin therapy (27), and GPC-3-derived peptide vaccines (28). Here, GPC3 is linked to hepatocellular carcinoma.